Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem®)

Journal of the Medical Association of Thailand

Volumn 91, Issue 7, 2008, Pages 980-988

  Leelarasamee, Amorn ^a   Rongrungruang, Yong ^a   Trakulsomboon, Suwanna ^a   Pongpech, Pintip ^b   Thanawattanawanich, Peeracha ^c   Jithavech, Ponsiree ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c Pharma Nueva Co Ltd   (Thailand)

Author keywords

Bioequivalence study; Generic meropenem; Serum inhibition assay

Indexed keywords

GENERIC DRUG; MAPENEM; MEROPENEM;

ADULT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INHIBITION; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUGS, GENERIC; HUMANS; MALE; THERAPEUTIC EQUIVALENCY; THIENAMYCINS; TREATMENT OUTCOME;

EID: 48249150696     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Dreetz M, Hamacher J, Eller J, Borner K, Koeppe P, Schaberg P et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 1996; 40: 105-9.
2. Raveh D, Yinnon AM, Broide E, Rudensky B. Susceptibilities of ESBL-producing enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid. Chemotherapy 2007; 53: 185-9.
3. Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC β-lactamase-producing organisms. Annals Pharmacotherapy 2007; 41: 1427-35.
4. von Eiff C, Peters G. In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci. J Antimicrob Chemother 1996; 38: 259-63.
5. Mastoraki E, Michalopoulos A, Kriaras I, Mouchtouri E, Falagas M, Karatza D et al. Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect 2008; 56: 35-9.
6. Jaruratanasirikul S, Sriwiriyajan S. Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health 2003; 34: 627-9.
7. Allegranzi B, Cazzadori A, Di Perri G, Bonora S, Berti M, Franchino L, et al. Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid. J Antimicrob Chemother 2000; 46: 319-22.
8. Bennett JV, Brodie JL, Benner EJ, Kirby WM. Simplified, accurate method for antimicrobial assay of clinical specimens. Appl Microbiol 1966; 14: 170-7.
9. USP 24-NF 19. The United States Pharmacopeial Convention Inc. Rockville, 2002, USA.
10. Kongthaisong M, Na-Bangchang K, Mungthin M, Sinchaipanid N, Tan-Ariya P. Comparison of the bioequivalence of three oral formulations of dihydroartemisinin based on ex vivo blood schizontocidal activities against Plasmodium falciparum. Am J Trop Med Hyg 2004; 71: 703-10.
11. Frank RG. The Ongoing Regulation of Generic Drugs. New Engl J Med 2007; 357: 1993-6.
12. Leelarasamee A, Tatong W, Kasattut N, Sriboonruang T, Panomvana Na Ayudhya D. Bioequivalence study of clindamycin phosphate injection (Clinott-P) in Thai healthy volunteers. J Med Assoc Thai 2006; 89: 683-9